+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prophylactic use of tranexamic acid after vaginal delivery reduces the risk of primary postpartum hemorrhage



Prophylactic use of tranexamic acid after vaginal delivery reduces the risk of primary postpartum hemorrhage



Journal of Maternal-Fetal and Neonatal Medicine 2019: 1-9



Postpartum hemorrhage (PPH) is responsible for about 25% of maternal deaths worldwide. Antifibrinolytic agents, mainly tranexamic acid, have been demonstrated to reduce maternal blood loss and need for transfusion requirements at delivery in some settings. The aim of this meta-analysis of randomized controlled trials (RCTs) was to evaluate the effectiveness of tranexamic acid for the prevention of PPH after vaginal delivery. The search was conducted using electronic databases from the inception of each database through February 2018. Review of articles also included the abstracts of all references retrieved from the search. No restrictions for language or geographic location were applied. Selection criteria included RCTs comparing the prophylactic use of tranexamic acid after vaginal delivery with control (either placebo or no treatment). Trials in women undergoing cesarean delivery and trials in women with established PPH were excluded. The primary outcome was the incidence of primary PPH. The summary measures were reported as summary relative risk (RR) with 95% confidence interval (CI) using the random-effects model of DerSimonian and Laird. Four RCTs, including 4671 participants, evaluating tranexamic acid usually 1 g intravenous (IV) within 10 min after vaginal delivery in addition to oxytocin, cord traction, and uterine massage, at or near term for prevention of primary PPH, defined mostly as blood loss ≥500 mL in the first 24 h following delivery, were analyzed. Women who received prophylactic tranexamic acid after vaginal delivery had a significantly lower incidence of primary PPH (8.7 versus 11.4%; RR 0.61, 95% CI 0.41-0.91) and lower mean blood loss mean difference (MD) -84.74 mL, 95% CI -109.76 to -59.72). The risk of thrombotic events was not increased in the tranexamic acid group. Prophylactic tranexamic acid 1 g IV within 10 min after vaginal delivery reduces the risk of primary PPH.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446444

Download citation: RISBibTeXText

PMID: 30704334

DOI: 10.1080/14767058.2019.1571576


Related references

Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials. Journal of Maternal-Fetal and Neonatal Medicine 2018: 1-6, 2018

The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum haemorrhage: a double-blind randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology 55(1): 53-58, 2015

Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. Journal of Maternal-Fetal and Neonatal Medicine 29(10): 1617-1622, 2016

Study protocol. TRAAP - TRAnexamic Acid for Preventing postpartum hemorrhage after vaginal delivery: a multicenter randomized, double-blind, placebo-controlled trial. Bmc Pregnancy and Childbirth 15(): 135-135, 2016

Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 133(3): 312-315, 2017

High-dose tranexamic acid for treating postpartum haemorrhage after vaginal delivery. British Journal of Anaesthesia 114(2): 339-341, 2015

Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention?: A systematic review and meta-analysis. Medicine 96(1): E5653, 2017

Intramuscular versus intravenous prophylactic oxytocin for postpartum hemorrhage after vaginal delivery: a randomized controlled study. Archives of Gynecology and Obstetrics 294(5): 911-916, 2016

Risk of Tranexamic Acid for Treatment of Postpartum Hemorrhage. American Journal of Kidney Diseases 69(1): 160, 2018

The effect of prophylactic oral tranexamic acid plus buccal misoprostol on blood loss after vaginal delivery: a randomized controlled trial. Journal of Maternal-Fetal and Neonatal Medicine 2017: 1-7, 2017

Risk factors for postpartum hemorrhage after vaginal delivery of twins. Journal of Nippon Medical School 74(6): 414-417, 2007

Tranfusion risk: is "two-step" vaginal delivery a risk for postpartum hemorrhage?. Journal of Maternal-Fetal and Neonatal Medicine 28(18): 2172-2175, 2016

Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery. American Journal of Obstetrics and Gynecology 209(1): 51.E1-6, 2013

Risk factors for early postpartum hemorrhage (PPH) in the first vaginal delivery, and obstetrical outcomes in subsequent pregnancy. Journal of Maternal-Fetal and Neonatal Medicine 28(8): 932-937, 2016

Carbetocin im injection vs oxytocin iv infusion for prevention of postpartum hemorrhage in women at risk following vaginal delivery. American Journal of Obstetrics & Gynecology 185(6 Supplement): S216, December, 2001